Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM39SEK)

Drug Name

BE-22179 Drug Info

Synonyms

BE 22179; AC1L4UUG; AC1Q6NP2; SCHEMBL14221468; FD-179; n,n'-[(1r,7s,14r,20s)-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triacontane-7,20-diyl]bis(3-hydroxyquinoline-2-carboxamide); 3-hydroxy-N-[(1R,7S,14R,20S)-7-[(3-hydroxyquinoline-2-carbonyl)amino]-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-20-yl]quinoline-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Terminated	[1]

Cross-matching ID

PubChem CID: 9941484
TTD Drug ID: DM39SEK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[3]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[5]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[3]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[6]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[3]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[7]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004286)
2	A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity. J Antibiot (Tokyo). 1994 Feb;47(2):129-35.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
5	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
6	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
7	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
8	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.